Funding Round Overview

Lila Sciences announced a Series A round on December 5, 2025 totaling $350,000,000 led by Braidwell. AI drug discovery startup Lila Sciences raised $350 million Series A co-led by Braidwell and Collective Global. $350M Series A for AI drug discovery.

Deal Highlights

• Capital involved: $350,000,000.
• Round: Series A.
• Investors: Braidwell, Collective Global.

Company and Sector Context

Lila Sciences builds in the healthcare ai sector, one of the most active areas in AI investment today. Based in United States, the company is part of a global wave of startups scaling AI into production across regulated and enterprise environments.

How the Capital Helps

Disclosed details include $350M Series A for AI drug discovery. In healthcare ai, speed to market and access to high-quality talent often determine category leadership.

Competitive Landscape

Funding activity in healthcare ai continues to intensify as incumbents and startups race to ship reliable AI systems. This round signals ongoing investor confidence in differentiated technology and defensible distribution.

Looking Ahead

This funding positions Lila Sciences for continued growth in the healthcare ai landscape. As AI adoption accelerates across industries, deals like this signal where capital and strategic attention are moving next.